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APOE 𝜀4 (apoE4) polymorphism is the main genetic determinant of sporadic Alzheimer’s disease (AD). A dietary approach
(Fortasyn) including docosahexaenoic acid, eicosapentaenoic acid, uridine, choline, phospholipids, folic acid, vitamins B12, B6,
C, and E, and selenium has been proposed for dietary management of AD. We hypothesize that the diet could inhibit AD-like
pathologies in apoE4 mice, specifically cerebrovascular and connectivity impairment. Moreover, we evaluated the diet effect on
cerebral blood flow (CBF), functional connectivity (FC), gray/white matter integrity, and postsynaptic density in aging apoE4mice.
At 10–12 months, apoE4 mice did not display prominent pathological differences compared to wild-type (WT) mice. However,
16–18-month-old apoE4 mice revealed reduced CBF and accelerated synaptic loss. The diet increased cortical CBF and amount
of synapses and improved white matter integrity and FC in both aging apoE4 and WT mice. We demonstrated that protective
mechanisms on vascular and synapse health are enhanced by Fortasyn, independent of apoE genotype. We further showed the
efficacy of a multimodal translational approach, including advanced MR neuroimaging, to study dietary intervention on brain
structure and function in aging.
1. Introduction
Extensive research has been pursued in search of an effective
therapy for Alzheimer’s disease (AD). However, no treatment
is yet available nor does it seem near. Preventive approaches
have therefore consistently emerged as key policy priorities
in recently formulated dementia strategies.These approaches
include modification of health-compromising behavior such
as lifestyle and dietary intake that may lead to AD. For
example, the Mediterranean diet (high consumption of fruit,
vegetables, and legumes, moderate consumption of fish, nuts,
and olive oil as the main source of fats) has been associated
with a reduced risk of AD [1, 2] and with a lower mortality
[3, 4]. The mechanisms via which diet influences the onset
and progression ofADpathology are still under investigation.
One possible mode of action is the beneficial effect of
nutrients, such as omega-3 long-chain polyunsaturated fatty
acids (n3-LCPUFAs) on the vascular system [4, 5].
Herewith n3-LCPUFAs will target the very early, asymp-
tomatic phase of the disease, in which (cerebro)vascular
impairment is the strongest contributor to the onset and
progression of neurodegenerative traits of typical AD and
dementia in general [6]. n3-LCPUFAs may diminish severity
of vascular risk factors, like atherosclerosis [7], high blood
pressure [8], and other cardiovascular diseases [7, 9–11],
which are risk factors for AD as well. Other nutrients may
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instead directly protect synaptic integrity. For instance, the
formation of phosphatidylcholine, the most common phos-
phatide in the brain and a major component of the synaptic
membrane, is enhanced due to presence of its precursors in
the diet [12, 13]. Several preclinical studies confirmed these
findings, showing that animals supplemented with the com-
bination of these membrane precursors showed increased
levels of brain phospholipids, dendritic spines, and neurite
outgrowth, with beneficial effects on cognition [14–18]. Based
on these findings, a novel multinutrient supplementation diet
called Fortasyn, comprising n3-LCPUFAs docosahexaenoic
acid (DHA) and eicosapentaenoic acid (EPA), besides other
precursors and cofactors for membrane synthesis, such as
uridine, choline, phospholipids, folic acid, vitamins B12, B6,
C, and E, and selenium, has been proposed for the dietary
management of AD [19]. To date, two randomized controlled
clinical trials have shown improvements in the delayed verbal
recall task and better cognitive performance in mild AD
patients supplemented with this nutrient combination [20–
22]. Although it has been recognized that Fortasyn addresses
specific nutritional needs in early AD and that it improves
functional connectivity as assessed by EEG [23], other pro-
cesses by which Fortasyn may influence the pathophysiology
of AD need to be further elucidated, and more studies are
required to confirm its efficacy.
Some studies suggested an interaction of the cholesterol
transporter apolipoprotein (apoE) with lipid-based dietary
intervention [24–26]. ApoE is a 34 kDa glycoprotein that
exists in three isoforms: apoE-𝜀2, apoE-𝜀3, and apoE-𝜀4,
which differ by one or two amino acid residues 112 and 158
[27]. This small difference strongly affects the conformation
and the structure of apoE and influences its ability to bind
lipids, receptors, and amyloid-𝛽 (A𝛽) [28]. ApoE polymor-
phic alleles have been identified as the main genetic deter-
minants of AD risk; specifically, apoE-𝜀4 has been associated
with increased toxicity and loss of neuroprotective function
in the pathogenesis of Alzheimer’s disease, dependent on or
independent of A𝛽 accumulation [29]. Importantly, some
of these processes are directly or indirectly linked to an
impaired vascular system [30–32]. The development of an
appropriate animal model, targeting the murine APOE gene
for replacement with the human APOE-𝜀4 (apoE-𝜀4/apoE4
mouse) [33], opened a window for new possibilities of char-
acterizing the apoE-𝜀4 phenotype and of studying the effects
of very early AD-like pathology development in relation with
lipid-based treatment. ApoE4 carrier mice exhibit an altered
lipid profile, with increased risk of atherosclerosis plaques
formation [33]. Altered behavior and cognitive deficits have
also been reported [34]. A previous study from our group
showed that a long-term dietary intervention with the For-
tasyn diet was able to reduce anxiety behavior in 10-month-
old apoE4 mice [35]. Transgenic AD mice on the same diet
showed restored cortical cerebral blood flow (CBF) and brain
structural integrity compared to wild-type mice [17].
Following these promising findings, we hypothesize that
a nutritional intervention with Fortasyn may be able to
rescue or prevent the occurrence of early AD-like pathologies
in apoE4 mice, such as cerebrovascular impairment and
concomitant brain connectivity loss. To test this hypothesis,
we evaluated the effect of the Fortasyn diet on cerebral
and plasma levels of fatty acids and sterols, cerebral blood
flow (CBF), gray and white matter integrity, functional
connectivity (FC), and postsynaptic density during aging in
12- and 18-month-old apoE4 mice.
2. Materials and Methods
2.1. Animals. The apoE-𝜀4 founder mice were originally
obtained from Taconic Transgenic Models (Hudson, NY,
USA) and a colonywas established at the RadboudUniversity
Medical Center (Radboudumc). ApoE4 mice were created
by targeting the murine apoE gene for replacement with the
human apoE-𝜀4 alleles cultured in E14TG2a embryonic stem
(ES) cells as described previously [36]. Resulting chimeras
were backcrossed to C57BL/6J mice for 8 generations. The
line was derived by embryo transfer and is maintained by
inbreeding homozygous mice. For the present study, male
and female apoE4 breeder mice were used to generate
homozygous apoE4 offspring (3rd generation).
C57BL/6J wild-type (WT) mice, obtained from our
colony at the Radboudumc, were used as controls. Through-
out the experiment animals were housed in groups of 2–7
mice per cage in a controlled environment, homogenously
illuminated by normal fluorescent room light at 60 lux, with
room temperature at 21∘C, and an artificial 12 : 12 h light : dark
cycle (lights on at 7 am). Food and water were available ad
libitum.
The experiments were performed according to Dutch
federal regulations for animal protection. The Veterinary
Authority of the Radboudumc, Netherlands, approved all the
protocols within this study (RU-DEC 2011-058).
2.2. Diets and Timeline of Experimental Design. Starting at
2 months of age, mice were randomly divided into two
groups; animals were fed either with control diet or with
Fortasyn diet that differed with respect to the presence of
a specific combination of dietary precursors and cofactors,
that is, uridine, docosahexaenoic acid, eicosapentaenoic acid,
choline, phospholipids, folic acid, vitamins B12, B6, C, and
E, and selenium (Table 1). Both diets were isocaloric and
based on AIN-93M [37] with 5% fat. The control diet
contained 1.9% soy oil, 0.9% coconut oil, and 2.2% corn oil;
the Fortasyn diet contained 0.1% coconut oil, 1.9% corn oil,
and 3.0% fish oil. The Fortasyn-based diet contains a specific
multinutrient composition comprising nucleotides, omega-3
PUFAs, choline, B vitamins, phospholipids, and antioxidants
(Table 1). Diets were manufactured and pelleted by Ssniff
(Soest, Germany) and stored at −20∘C until use. The first
group of mice underwent MR imaging at 11 (average age:
10.6 ± 0.1 months) to 12 (average age: 12.3 ± 0.1 months)
months of age and was sacrificed immediately thereafter.The
second group was scanned at 16 months of age (average age:
16.2±0.1months) and sacrificed at 18 months of age (average
age: 17.9 ± 0.1 months). The timeline of the experimental
design is illustrated in Figure 1. The sample size of minimal
6 mice (12-month: WT-control 𝑛 = 9, WT-Fortasyn 𝑛 = 9,
apoE4-control 𝑛 = 8, and apoE4-Fortasyn 𝑛 = 10; 18-month:
WT-control 𝑛 = 10, WT-Fortasyn 𝑛 = 10, apoE4-control
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Table 1: Compositions of the experimental diets used, based on
AIN-93M [37] with minor revisions.
Source
Dietary groups
Control
[g/100 g]
Fortasyn
[g/100 g]
Corn starch 35.57 33.12
Casein 14.00 14.00
Corn dextrin 15.5 15.50
Sucrose 10.00 10.00
Dextrose 10.00 10.00
Fibers 5.00 5.00
Mineral mix (AIN-93 M-MX) 3.50 3.50
Vitamin mix (AIN-93-VX) 1.00 1.00
Fats
Soy oil 1.900 —
Coconut oil 0.900 0.100
Corn oil 2.200 1.870
Fish oil — 3.030
Additions
l-Cysteine 0.180 0.180
Choline bitartrate (41.1% choline) 0.250 0.250
tert-Butylhydroquinone 0.0008 0.0008
Pyridoxine–HCL — 0.00328
Folic acid (90%) — 0.00067
Cyanocobalamin (0.1% in mannitol) — 0.00350
Ascorbic acid (100% pure) — 0.160
dl-𝛼-Tocopheryl acetate (500 IU/g) — 0.4650
UMP disodium (24% H
2
O) — 1.0
Choline chloride (74.576%) — 0.402
Soy lecithin — 0.402
Sodium selenite (46%min) — 0.00023
Energy (kcal/100 g chow) 376.9 367.1
Birth
Start diets
0 2 4 10 12 14 16 18
MRI & † MRI & †
Months
Figure 1: Timeline of experimental design. Starting from 2 months
of age, mice were randomly divided into two groups; animals were
fed either with control diet or with Fortasyn diet. The first group of
mice underwent MR imaging (MRI) at 11 to 12 months of age and
were sacrificed (†) immediately thereafter. The second group was
sacrificed after MRI at 18 months of age.
𝑛 = 10, and apoE4-Fortasyn 𝑛 = 6) per group was chosen
based on formal calculation of power as described in the
approved protocols (RU-DEC 2011-058).
2.3. MR Imaging. MRI measurements were performed on
an 11.7 T BioSpec Avance III small animal MR system
(Bruker BioSpin, Ettlingen, Germany) equipped with an
actively shielded gradient set of 600mT/m and operated by
ParaVision 5.1 software between 8 am and 8 pm. We used
a circular polarized volume resonator for signal transmis-
sion and an actively decoupled mouse brain quadrature
surface coil for signal reception (Bruker BioSpin). During
the MR experiments, low-dose isoflurane was used (3.5%
for induction and ∼1.5% for maintenance), slightly adjusted
throughout the experiment to maintain a fast and stable
breathing frequency (>130 bpm). The mice were placed in a
stereotactic device in order to immobilize the head. Body
temperature was measured with a rectal thermometer and
maintained at 37∘C by a heated air flow device.
After standard adjustments and shimming, gradient echo
(GE) T
2
∗-weighted images covering the entire mouse brain
were acquired for anatomical reference.
To study brain perfusion under resting conditions, we
used a flow-sensitive alternating inversion recovery arterial
spin labelling (FAIR ASL) technique [17, 38]. Briefly, fif-
teen images with increasing inversion times (TIs) (40ms–
3000ms) were obtained for the T
1
calculations, amounting to
a total scan time of 12 minutes. Inversion recovery data from
the imaging slice were acquired after selective inversion inter-
leaved with nonselective inversion. Relative cerebral blood
flow (CBF) was measured in the cortex, in the hippocampus,
and in the thalamus based on [17].
Diffusion of water was imaged as described previously
[35, 39]. In short, 22 axial slices covering the whole brain
were acquired with a four-shot SE-EPI protocol. B0 shift
compensation, navigator echoes, and an automatic correction
algorithm to limit the occurrence of ghosts and artefacts were
implemented. Encoding b-factors of 0 s/mm2 (b0 images;
5x) and 1000 s/mm2 were used and diffusion-sensitizing
gradients were applied along 30 noncollinear directions in
three-dimensional space.
The diffusion tensor was estimated for every voxel using
the PATCH algorithm [40]; mean water diffusivity (MD)
and fractional anisotropy (FA) were derived from the tensor
estimation following a protocol as described elsewhere [35].
MD and FA values were measured in several white matter
(WM) and gray matter (GM) areas, which were manually
selected based on an anatomical atlas [41].
The resting-state fMRI (rsfMRI) datasets were first
realigned using a least-squares method and rigid-body trans-
formation with Statistical Parametric Mapping (SPM) mouse
toolbox (SPM5, University College London; http://www.fil
.ion.ucl.ac.uk/spm/; [42]).Mean andmaximumdisplacement
across the six degrees of freedom (along the 𝑥-, 𝑦-, and 𝑧-
axes and on three rotation parameters pitch, roll, and yaw)
were measured in each mouse. The mean SE-EPI images
of each mouse were then used to generate a study-specific
template through linear affine and nonlinear diffeomorphic
transformation (ANTs. v1.9; http://picsl.upenn.edu/ANTS/).
Visual inspection of the normalized dataset was performed
to check for possible normalization biases. On the template,
15 areas were selected in left and right hemisphere. The
selected regions were based on previous work in functional
connectivity in mice [43] and included left and right dorsal
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hippocampus, left and right ventral hippocampus, left and
right auditory cortex, left and right motor cortex, left and
right somatosensory cortex, and left and right visual cortex.
All cortical ROIs were selected 1-2 voxels away from the
edge of the cortex, to minimize the impact of susceptibility-
weighted artefacts, which are more prominent in areas of
different tissues interface (e.g., near the skull or near the ear
canals). After motion regression, in-plane spatial smoothing
(0.4 × 0.4mm), linear detrending, and temporal high-pass
filtering (cutoff at 0.01Hz) were applied to compensate
for small across-mouse misregistration and temporal low-
frequency noise. FC group comparison between ROIs was
calculated from the BOLD time series using total cor-
relation and partial correlation analyses implemented in
FSLNets (FSLNets v0.3; http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/).
Pearson’s correlation values were Fisher transformed to 𝑍-
scores for group comparisons and statistical analysis.
2.4. Brain Tissue Preparation. Directly following the MR
measurements at 12 and 18 months of age, anaesthetised
mice were sacrificed by transcardial perfusion with 0.1M
phosphate buffered saline (PBS). The perfused brains were
cut sagittally and the right hemispheres were snap frozen
in liquid nitrogen and stored at −80∘C, before further bio-
chemical processing. The left hemispheres were immersion
fixated for 15 h at 4∘C in 4% paraformaldehyde fixative and
thereafter stored in 0.1M PBSwith 0.01% sodium azide at 4∘C
for immunohistochemical staining.
2.5. Immunohistochemistry: PSD95. Eight series of 30 𝜇m
coronal sections were cut through the brain using a slid-
ing microtome (Microm HM 440 E, Walldorf, Germany)
equipped with an object table for freeze sectioning at −60∘C.
The tissue was stained for postsynaptic density with poly-
clonal rabbit anti-PSD95 antibody (1 : 2000; Abcam Cat #
ab18258, RRID:AB 444362) using one complete series of
brain sections. Immunohistochemistry was performed using
standard free-floating labelling procedures, as described pre-
viously.
2.6. Quantification. The stained sections were analysed using
a Zeiss Axioskop microscope equipped with hardware and
software of Microbrightfield (Williston, VT, USA). Brain
regions were based on the mouse brain atlas of Franklin and
Paxinos (third edition, 2008) and quantified in five regions
of the hippocampus: the inner molecular layer (IML), outer
molecular layer (OML), cornus ammonis 1 (CA1), CA2, and
CA3. Additionally, two regions in the cortex corresponding
to the visual and somatosensory cortex were analysed. The
relevant regions were digitized at 100x magnification with
immersion oil using Stereo Investigator. The quantification
of the photographs was performed using Image J (Image J,
U.S. National Institutes ofHealth, Bethesda,Maryland,USA).
The contrast was manually enhanced, following the same
procedure for all digitized images, and the amount of tissue
stained was measured with a threshold-based approach.
2.7. Biochemical Analyses. Serum and brain sterol levels
were measured by gas-chromatography-mass-spectrometry-
selected-ion-monitoring (GC-MS-SIM) as described in detail
previously [44]. The cerebellum of the right hemisphere
was homogenized and sterols were extracted overnight by
chloroform/methanol trimethylsilylation prior to GC-MS-
SIM analysis [44]. Brain fatty acid analyses were performed
with a part of the brain homogenate (olfactory bulb and part
of frontal cortex), as described previously [35].
2.8. Statistics. For the statistical analysis, IBM SPSS 20 soft-
ware (IBMCorporation,NewYork,NY,USA)was used. Since
the setup of the current study was designed to determine the
effects of diet supply at two stages in which apoE4 mice may
develop different neuropathological traits of AD, statistical
analyses were performed separately for the two age-points.
Multivariate ANOVA (MANOVA) with Bonferroni cor-
rections, using body weight as covariate when necessary, was
conducted with between-group-factors genotype and diet to
analyse possible differences in all the other parameters. If the
Bonferroni post hoc test indicated a significant interaction
between genotype and diet, the data were split for the
concerning factor and thereafter analysed again with the
MANOVA. Statistical significance was set at 𝑝 ≤ 0.05. All
data are expressed as mean ± SEM.
3. Results
Mortality rate in the apoE4 mice was normal until age of 18
months (<8% total mortality rate) in both diet groups. None
of the WT animals died during the experiment.
3.1. Body Weight
10–12-Month-Old Mice. Body weight was measured at 10 and
12 months of age (Figure 2(a)). Statistical analysis revealed a
significant genotype × diet interaction (𝑝 = 0.050). ApoE4
andWTmice fed the Fortasyn diet were significantly heavier
than animals on control diet (ApoE4: 𝐹(1, 18) = 46.6, 𝑝 <
0.001; WT: 𝐹(1, 17) = 31.2, 𝑝 < 0.001). ApoE4 mice on
Fortasyn were significantly heavier compared toWTmice on
Fortasyn (𝐹(1, 17) = 7.3, 𝑝 = 0.015).
At the start of the MRI measurements a significant
genotype × diet interaction on body weight was found
(𝑝 = 0.018). Again, all animals on Fortasyn diet showed an
increased body weight compared to animals on control diet
(ApoE4: 𝐹(1, 18) = 50.1, 𝑝 < 0.001; wild-type: 𝐹(1, 17) = 6.7,
𝑝 = 0.019). ApoE4 mice on Fortasyn were heavier than wild-
type mice on the same diet (𝐹(1, 17) = 7.6, 𝑝 = 0.013).
16–18-Month-Old Mice. Body weight was measured at 16 and
18months of age (Figure 2(b)). In bothmeasurements, ApoE4
mice weighed significantly less than WT mice (16 months:
𝐹(1, 33) = 10.3, 𝑝 = 0.003; 18 months: 𝐹(1, 33) = 9.0,
𝑝 = 0.005). Both at 16 and at 18 months of age, all animals
on Fortasyn were heavier than animals on control diet (16
months: 𝐹(1, 33) = 5.6, 𝑝 = 0.024; 18 months: 𝐹(1, 33) = 4.5,
𝑝 = 0.042).
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Figure 2: Body weight was measured in 10–12-month-old (a) and 16–18-month-old ApoE4 and wild-type (WT) mice. (a) At 10 months of
age, ApoE4 and also wild-type mice on Fortasyn were significantly heavier than on control diet (ApoE4: 𝑝 < 0.001; wild-type: 𝑝 < 0.001).
Only on Fortasyn diet was a genotype effect found showing a higher weight of ApoE4mice compared with wild-type mice (𝑝 = 0.015). Again
at 12 months of age, all animals on Fortasyn diet showed an increased body weight compared to animals on control diet (ApoE4: 𝑝 < 0.001;
wild-type: 𝑝 = 0.019). ApoE4 mice on Fortasyn were heavier than wild-type mice on the same diet (𝑝 = 0.013). (b) At 16 and also 18 months
of age, ApoE4 mice were significantly lighter than wild-type mice (16-month: 𝑝 = 0.003; 18-month: 𝑝 = 0.005). Furthermore, all animals on
Fortasyn were heavier than animals on control diet (16-month: 𝑝 = 0.024; 18-month: 𝑝 = 0.042). ∗𝑝 ≤ 0.05; ∗∗𝑝 ≤ 0.01; ∗∗∗𝑝 ≤ 0.001.
3.2. Magnetic Resonance Imaging
3.2.1. Cerebral Blood Flow. To study group-related differences
on cerebrovascular health, we measured cerebral blood flow
(CBF) with a flow-sensitive MRI technique (FAIR ASL).
Three regions of interest (ROIs) on the left and right brain
hemispheres were analysed: cortex, hippocampus, and tha-
lamus. Since no intraindividual differences in CBF between
right and left hemispheres were detected between mice
groups (data not shown), values from both sides were aver-
aged. In all measures, CBF was not significantly influenced
by body weight.
In the 12-month-old mice, we detected a genotype × diet
interaction in the thalamus (𝑝 = 0.045). In detail, Fortasyn
diet increased thalamic CBF (𝐹(1, 16) = 5.0, 𝑝 = 0.040)
more strongly in WT mice than in the apoE4 littermates
(Figure 3(a)).
In the 18-month-old mice (Figure 3(b)), CBF was
decreased in the cortex (𝐹(1, 31) = 4.4, 𝑝 = 0.044) and in
the thalamus (𝐹(1, 31) = 5.7, 𝑝 = 0.023) of apoE4 mice as
compared to WT mice. Cortical CBF was increased by the
Fortasyn diet in both WT and apoE4 mice (𝐹(1, 31) = 4.7,
𝑝 = 0.038).
3.2.2. Diffusion Tensor Imaging. Quantitative assessment of
diffusion tensor derived indices was performed for ROIs
drawn in white and gray matter regions to assess genotype
and diet effects in apoE4 and nontransgenic WT mice
(Figure 4(a)).
Fractional Anisotropy. In the 12-month-old mice, we did not
detect any significant differences in white matter FA between
the groups of mice (Figure 4(b)).
At 18 months of age (Figure 4(c)), Fortasyn fed mice
showed a lower FA at −0.7mm in the corpus callosum
compared to control fed mice (𝐹(1, 31) = 4.7, 𝑝 = 0.008).
Mean Diffusivity. In the 12-month-old mice, the MANOVA
revealed a genotype × diet interaction for MD in the motor
cortex (𝑝 = 0.024, Figure 4(b)).
In detail,WTmice on Fortasyn diet had higherMD in the
motor cortex than wild-type mice on control diet (𝐹(1, 14) =
9.2, 𝑝 = 0.009). Furthermore apoE4 mice on Fortasyn diet
had a lower MD in the motor cortex than WT mice on
Fortasyn (𝐹(1, 17) = 5.2, 𝑝 = 0.036). Fortasyn diet decreased
MD in the auditory cortex (𝐹(1, 29) = 4.9, 𝑝 = 0.034) and
in the somatosensory cortex (𝐹(1, 29) = 7.9, 𝑝 = 0.009)
compared to control diet, irrespective of genotype.
At 18 months of age (Figure 4(c)), apoE4 mice displayed
an increased MD in the auditory cortex (𝐹(1, 29) = 5.6, 𝑝 =
0.025) compared to WT mice.
3.2.3. rsfMRI
Total Correlation Analyses. To compare the FC patterns
between different genotypes and diets, rsfMRI data were
statistically analysed based on total correlation (Figure 5) and
partial correlation (Figure 6).
At 12 months of age, multivariate ANOVA (MANOVA)
revealed some significant genotype but no diet effects in
apoE4 compared to WT mice. More specifically, apoE4 mice
showed reduced FC between the right auditory cortex and the
left dorsal hippocampus (𝐹(1, 24) = 5.1, 𝑝 = 0.033) and also
between the left visual cortex and the right auditory cortex
(𝐹(1, 24) = 5.5, 𝑝 = 0.028).
At 18 months of age, theMANOVA demonstrated several
significant genotype and diet effects. In detail, apoE4 mice
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Figure 3: Cerebral blood flow (CBF) as measured with a flow-sensitive MRI technique (FAIR ASL) at 12 months and 18 months of age in
C57BL/6J wild-type control mice and ApoE4 transgenic mice on control diet or Fortasyn diet. Three regions of interest (ROIs) on the left
and right brain hemispheres were analysed: cortex, hippocampus, and thalamus. (a) In the 12-month-old mice we detected a genotype × diet
interaction in the thalamus (𝑝 = 0.045). Fortasyn diet increased thalamic CBF (𝑝 = 0.040) more strongly in wild-type mice than in the apoE4
littermates. (b) In the 18-month-old mice, CBF was decreased in the cortex (𝑝 = 0.044) and in the thalamus (𝑝 = 0.023) of apoE4 mice as
compared to wild-type mice. Cortical CBF was increased by the Fortasyn diet in both wild-type and apoE4 mice (𝑝 = 0.038). ∗𝑝 ≤ 0.05;
∗∗
𝑝 ≤ 0.01; ∗∗∗𝑝 ≤ 0.001.
had significant lower FC between cortical and hippocampal
regions but also between cortical regions themselves.Notably,
Fortasyn was able to increase the hippocampal FC and
also FC between the visual and retrosplenial cortex to the
hippocampus.
The MANOVA revealed genotype × diet interactions in
the left auditory cortex to retrosplenial cortex (𝑝 = 0.011), in
the right auditory cortex to right somatosensory cortex (𝑝 =
0.05), and in the left somatosensory cortex to retrosplenial
cortex (𝑝 = 0.025). ApoE4 mice on control diet showed a
reduced FC between left auditory cortex and retrosplenial
cortex (𝐹(1, 15) = 17.9, 𝑝 = 0.001), right auditory cortex and
right somatosensory cortex (𝐹(1, 15) = 4.9, 𝑝 = 0.042), and
left somatosensory cortex and retrosplenial cortex (𝐹(1, 15) =
18.2, 𝑝 = 0.001), which were not observed in ApoE4 mice on
Fortasyn diet.
Moreover, compared to their transgenic littermates on
control diet only apoE4 mice on Fortasyn displayed an
increased FC between left auditory cortex and retrosplenial
cortex (𝐹(1, 11) = 13.0, 𝑝 = 0.004), right auditory cortex and
right somatosensory cortex (𝐹(1, 11) = 9.9, 𝑝 = 0.009), and
left somatosensory cortex and retrosplenial cortex (𝐹(1, 11) =
10.2, 𝑝 = 0.009).
Partial Correlation Analyses. At 12 months of age, significant
genotype and diet effects were shown using MANOVA
(Figure 6). In detail, apoE4 mice showed a reduced FC
between left dorsal and ventral hippocampus (𝐹(1, 24) = 4.7,
𝑝 = 0.040). Additionally, animals on Fortasyn diet showed an
increased partial correlation in the interhemispheric connec-
tion between left and right ventral hippocampus (𝐹(1, 24) =
7.3, 𝑝 = 0.012).
At 18 months of age, the MANOVA showed several
significant genotype and diet effects (Figure 6). ApoE4 mice
had a reduced FC between the right auditory cortex and
the right motor cortex (𝐹(1, 26) = 16.4, 𝑝 < 0.001). The
Fortasyn diet increased FC between left and right motor
cortices (𝐹(1, 26) = 7.1, 𝑝 = 0.013) but slightly reduced FC
between left and right dorsal hippocampus (𝐹(1, 26) = 4.4,
𝑝 = 0.045).
MANOVA also revealed a genotype × diet interaction
between right auditory cortex and right somatosensory cor-
tex, 𝑝 = 0.010. Fortasyn diet increased partial correlation in
apoE4 mice compared to WT between right auditory cortex
and right somatosensory cortex (𝐹(1, 12) = 8.1, 𝑝 = 0.015).
3.3. Postsynaptic Density-95 (PSD-95) Protein. Density of
postsynaptic density proteins was visualised and quantified
immunohistochemically in various cortical and hippocampal
areas with polyclonal rabbit anti-PSD-95. At 12 months,
we did not observe significant differences between groups
(Figure 7). At 18 months, reduced PSD-95 levels were seen
in the sensory cortex of apoE4 mice compared to WT mice
(𝐹(1, 33) = 5.8, 𝑝 < 0.021). Fortasyn diet increased levels of
PSD-95 in the sensory cortex (𝐹(1, 33) = 6.7,𝑝 < 0.014), CA3
area (𝐹(1, 31) = 9.9, 𝑝 < 0.004), and IML (𝐹(1, 31) = 9.9,
𝑝 < 0.004), irrespective of genotype. No genotype × diet
interactions were observed.
3.4. Fatty Acids. Fatty acid content was analysed in the brains
of apoE4 and WT mice (Supplementary Material + Supple-
mentary Table 1 available online at http://dx.doi.org/10.1155/
2016/6846721). At both 12 and 18 months of age, increased
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Figure 4: Quantitatively assessed diffusion tensor derived indices at 12 months and 18 months of age in C57BL/6J wild-type control mice and
ApoE4 transgenic mice on control diet or Fortasyn diet. (a) Fractional anisotropy (FA) and mean diffusivity (MD) were measured for ROIs
drawn in white and gray matter regions, respectively. (b) In 12-month-old mice, no differences in FA were observed. In the 12-month-old
mice, the wild-type mice on Fortasyn diet had higher MD in the motor cortex than wild-type mice on control diet (𝑝 = 0.009). Furthermore
apoE4 mice on Fortasyn diet had a lower MD in the motor cortex than wild-type mice on Fortasyn (𝑝 = 0.036). Fortasyn diet decreased MD
in the auditory cortex (𝑝 = 0.034) and in the somatosensory cortex (𝑝 = 0.009) compared to control diet, irrespective of genotype. (c) At 18
months of age, Fortasyn fed mice had a lower FA at −0.7mm in the corpus callosum than control fed mice (𝑝 = 0.008). At 18 months of age,
apoE4 mice displayed an increased MD in the auditory cortex (𝑝 = 0.025). ∗𝑝 ≤ 0.05; ∗∗𝑝 ≤ 0.01; ∗∗∗𝑝 ≤ 0.001.
relative levels of omega-3 fatty acids (𝑝 = 0.000) and an
increased ratio of omega 3/6 were found in Fortasyn fedmice
compared to their littermates on control diet (𝑝 = 0.000).
At 18 months of age, ApoE4 mice displayed significantly
increased relative arachidonic acid (𝑝 = 0.022) and relative
omega-6 content (𝑝 = 0.038) compared to wild-type mice.
For a detailed overview see the fatty acid section in the
Supplementary Material and Supplementary Table 1.
3.5. Sterol Levels. Sterol levels were determined in the blood
plasma (serum) and in the cerebellum of the brain. The
main findings are described below; for all detailed results see
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Figure 5: Resting-state functional connectivity (FC) based on total correlation analyses of 15 regions of interest (ROIs) in the mouse brain.
Total correlation matrices of wild-type and apoE4 at 12 and 18 months of age, both on Fortasyn and control diets. At 12 months of age,
multivariate ANOVA (MANOVA) revealed some significant genotype but no diet effects in apoE4 compared to wild-type mice. More
specifically, apoE4 mice showed reduced FC between the right auditory cortex and the left dorsal hippocampus (𝑝 = 0.033) and also between
the left visual cortex and the right auditory cortex (𝑝 = 0.028). At 18 months of age, apoE4 mice had significant lower FC between cortical
and hippocampal regions but also between cortical regions themselves. Notably, Fortasyn was able to increase the hippocampal FC and also
FC between the visual and retrosplenial cortices to the hippocampus.
Supplementary Material and Supplementary Tables 2 and 3,
respectively.
3.5.1. Blood Serum. At 12 months of age, apoE4 mice dis-
played increased level of the cholesterol precursor, dihy-
drolanosterol (𝑝 = 0.000), compared to WT mice. At 12
months of age, apoE4mice on control diet had higher levels of
lathosterol (𝑝 = 0.002) and lanosterol (𝑝 = 0.003) compared
to WT mice on control diet.
At 18 months of age, apoE4 and WT mice on control
diet displayed increased levels of campesterol (𝑝 = 0.000),
sitosterol (𝑝 = 0.016), lanosterol (𝑝 = 0.010), desmosterol
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Figure 6: Resting-state functional connectivity (FC) based on partial correlation analyses of 15 regions of interest (ROIs) in the mouse brain.
Total correlation matrices of wild-type and apoE4 at 12 and 18 months of age, both on Fortasyn and control diets. At 12 months of age, apoE4
mice showed a reduced FC pattern between left dorsal and ventral hippocampus (𝑝 = 0.040). Additionally, animals on Fortasyn compared
to control diet showed an increased partial correlation in the interhemispheric connection between left and right ventral hippocampus (𝑝 =
0.012). At 18 months of age, ApoE4 mice on both diets had a reduced FC between the right auditory cortex and the right motor cortex
(𝑝 < 0.001). The Fortasyn diet caused contrasting effects: a higher FC was found between left-to-right motor cortices (𝑝 = 0.013), but a
slight FC reduction was revealed between left and right dorsal hippocampus (𝑝 = 0.045). Fortasyn diet increased partial correlation in apoE4
mice compared to their wild-type littermates between left and right auditory cortex (𝑝 = 0.015) and between right auditory cortex and right
somatosensory cortex (𝑝 = 0.015). In wild-type mice FC between left somatosensory cortex and left auditory cortex (𝑝 = 0.041) was higher
in Fortasyn fed animals compared to control fed animals.
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Figure 7: Levels of postsynaptic density-95 (PSD-95) in various brain areas in wild-type mice and apoE4 mice on either control diet or
Fortasyn diet. (a) At 12 months, we did not find significant differences between groups. (b) At 18 months, reduced PSD-95 levels were seen
in the sensory cortex of apoE4 mice compared to wild-type mice (𝑝 = 0.021). Fortasyn diet increased levels of PSD-95 in the sensory cortex
(𝑝 = 0.014), CA3 area (𝑝 = 0.004), and IML (𝑝 = 0.004), irrespective of genotype. No genotype × diet interactions were observed. ∗𝑝 ≤ 0.05;
∗∗
𝑝 ≤ 0.01; ∗∗∗𝑝 ≤ 0.001.
(𝑝 = 0.000), 24OH-cholesterol (𝑝 = 0.002), and cholesterol
(𝑝 = 0.033) compared to apoE4 and WT mice on Fortasyn
diet.
3.5.2. Cerebellum. At 12 months of age, apoE4 and WT mice
on control diet demonstrated increased levels of lathosterol
(𝑝 = 0.003), campesterol (𝑝 < 0.000), and lanosterol (𝑝 =
0.001) in the cerebellum.
At 18 months of age, cerebellar cholesterol levels were
unchanged in ApoE4 mice compared to WT mice (𝑝 =
0.614). In control fed mice levels of campesterol and pre-
cursors of cholesterol, lathosterol, and lanosterol were higher
than in Fortasyn fed mice (campesterol, 𝑝 < 0.000; lathos-
terol, 𝑝 < 0.000; lanosterol, 𝑝 = 0.011).
4. Discussion
4.1. ApoE4 Mice as Model for the Early Asymptomatic Phase
in AD. In this study, we investigated the extent to which
apoE4 mice display cerebrovascular flaws, synaptic loss, and
connectivity during aging. The 𝜀4 allele of the apoE gene is
strongly associated with sporadic AD [45]. Among several
proposed mechanisms by which apoE4 promotes AD, there
are indications that apoE4 is less effective in synaptic repair
and remodelling processes compared to other isoforms [46,
47]. Moreover, apoE4 carriers are clearly more susceptible
to vascular brain damage (e.g., stroke, brain haemorrhage
[29, 30, 48]), and they display aberrant functional connectiv-
ity [49].
Similarly, the apoE4 mouse line exhibits increased risk
of developing vascular disorders and neuronal deficits due
to altered cholesterol metabolism, especially when chal-
lenged with a high-fat diet [33]. Recently we also described
spontaneous functional connectivity deficits in these mice,
possibly associated with cerebral blood flow reduction [50].
Because these deficits seem to be aggravated with aging we
investigated this mouse line at two different ages.
At 10–12 months of age, apoE4mice did not display many
differences compared to WT animals. Despite some slight
alterations in the sterol levels of 12-month-old apoE4 mice,
all other measured parameters including cerebral blood flow
and number of postsynapses were unaffected compared to
WT animals. Previously, we have shown that at this age also
cerebral blood volume, amount of presynaptic boutons, and
neurogenesis did not differ from WT mice [35]. The lack of
cerebrovascular alterations like a reduced CBF at this agemay
explain the absence of pathologies.
However at 16–18 months of age, apoE4 mice revealed
reduced CBF and accelerated neurodegeneration, which are
typical features of prodromal AD [51–54]. Specifically, we
detected reduced thalamic and cortical perfusion, reduced
cortical postsynaptic density, increased cortical mean dif-
fusivity (MD), and reduced fractional anisotropy (FA) in
white matter tracts. Similar changes in brain diffusivity, as
a biomarker for white and gray matter integrity, have been
reported in human apoE4 carriers [55–58]. These structural
modifications may be linked to the isoform-specific role
of apoE in synaptic development, dendrite formation, and
axonal guidance, which to some extent may be impaired
in apoE4 carriers [59]. Nevertheless, these results were not
consistent across different ages, suggesting that changes in
WM/GM microstructure properties may not directly reflect
an associated AD-like pathology [60]. Moreover, at this age
we measured a widespread reduction in functional connec-
tivity at rest, which was previously reported [17].
Overall, in line with other studies in this mouse model
[34], these findings suggest that the apoE4 mice sponta-
neously develop age- and apoE4-dependent accelerated brain
pathology.This is in agreement with human studies on apoE4
carriers showing a faster decline of CBF during aging [61, 62]
and reduced connectivity between cortical regions at old age
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[63–65]. However, the apoE4 mice exhibited relatively small
genotype effects like CBF decline and reduced connectivity
just at 18months of age and not at 12months of age.Therefore,
one could argue that an 18-month-old apoE4 mouse is at
most similar to a 65-year-old still healthy, possibly onlymildly
impaired human apoE4 carrier, showing no signs of dementia
yet and carrying no multiple risk factors and comorbidities.
It has been found, namely, that human apoE4 carriers often
carry multiple risk factors (genetic modifiers, comorbidities,
and lifestyle factors) that contribute significantly to synaptic
integrity. The only risk factor included in our mice was age,
combined with apoE4 genotype causing mild pathology.
A recent review on apoE-related biomarker profiles in
the early phase of AD further elucidates this relatively novel
concept of the apoE4 to be consideredmore as a vulnerability
factor rather than a pathogenic factor [66]. Based on this
idea, it is the interaction between these vulnerabilities and
the age-related pathological events that may trigger synaptic
loss, contributing to the development of AD. In our study,
this aging-dependency of apoE4 seemed confirmed, as most
of the biomarkers for brain deficits were identified only
in the 18-month-old apoE4 group, representing an early
stage of the disease, when complete early AD-like pathology
is still not fully developed. Holding this hypothesis, the
model becomes extremely attractive to study the effects of
nutritional intervention as a preventive strategy against early
AD-like pathology.
4.2. Dietary Intervention. In the current experiment we
fed the mice a specific multinutrient supplementation diet
designed to ameliorate synapse loss and to reducemembrane-
related pathology in AD by providing nutritional precursors
and cofactors to support neuronal membrane formation and
function [67]. This nutrient combination, called Fortasyn,
comprises uridine, docosahexaenoic acid, eicosapentaenoic
acid, choline, phospholipids, folic acid, vitamins B12, B6,
C, and E, and selenium. Some of the components in these
diets, such as omega-3 long-chain polyunsaturated fatty acids
(n3- LCPUFAs), have also been shown to improve vascular
health [5, 68–71].The results confirmed our initial hypothesis
that the Fortasyn diet has the potential to reduce the occur-
rence of vulnerabilities for AD by simultaneously improv-
ing cerebrovascular health and enhancing neuroprotective
mechanisms. However it is also possible that the capacity of
the diet to support membrane phospholipid synthesis could
underlie both the synapse formation/functional connectivity
and the effects on cerebrovascular functioning. Besides, the
combination of phosphatide precursors like n3-LCPUFAs,
uridine, and choline has proven to synergistically increase the
synthesis of synaptic proteins and phospholipids in the brain
[14–16].
These findings confirm novel important mechanisms by
which these diets may affect AD onset and development,
similar to earlier findings in a transgenic AD mouse model
[17]. Particularly, among the different parameters analysed,
the strongest and most consistent dietary effect in these stud-
ies involves the improvement of cerebrovascular health and
functional connectivity. Several epidemiological studies and
controlled trials showed a correlation between B vitamins,
n3-LCPUFAs, and MUFA (like oleic acid from olive oil
and nuts) and improvements in autonomic function, low-
ered blood pressure, reduced atherosclerosis, reduced total
homocysteine, and enhanced microvascular endothelium-
dependent vasodilation processes [4, 72, 73].
All these factors may contribute to an improved func-
tionality of the brain vasculature, with a beneficial effect
particularly in apoE4 mice, in which these pathologies are
aggravated. Interestingly, increased cortical CBF and levels
of postsynaptic markers were found in both apoE4 and
WT animals on Fortasyn diet; these findings suggest that
the diet had a similar effect in both genotypes and its
contribution is not determined by the apoE genotype. We
have also shown that the Fortasyn diet affected brain fatty
acid profiles in both genotypes (Supplementary Material,
Table 1), by decreasing the relative concentration of n6-
fatty acids (notably arachidonic acid), which is significantly
increased in the 18-month-old apoE4 mice compared to
WT, and by increasing the relative concentration of n3-
fatty acids (notably DHA) and monounsaturated fatty acids,
especially oleic acid. These supplementary results indicate
a replacement of n6 fatty acids from cell membranes in
favour of n3-LCPUFAs (reflected by the increased n3/n6
ratio), which has beneficial effects on membrane fluidity, and
neuronal transmission and signalling [74–76]. Furthermore,
we have shown that the Fortasyn diet similarly affected
serum (Supplementary Material Table 2) and brain sterol
level (Supplementary Material Table 3). In detail, in the
plasma of aged animals on Fortasyn we found decreased
levels of cholesterol but also of precursors like lanosterol and
derivates of cholesterol like 24OH-cholesterol. Notably, in
the cerebellum of aged animals on Fortasyn we detected a
decreased concentration of the cholesterol precursor lanos-
terol and increased level of a derivate of cholesterol, 24S-
hydroxycholesterol. In the brain, the enzyme, cholesterol 24S-
hydroxylase, converts cholesterol to 24S-hydroxycholesterol.
This mechanism is the most important pathway for the
elimination of brain cholesterol and the maintenance of
brain cholesterol homeostasis [77–80]. These results are
also in line with our previous study using another AD
mouse model overexpressing A𝛽. Here, another cholesterol
precursor, lathosterol, was decreased in the brain of Fortasyn
fed AD and WT mice, while again an increased cerebral
level of the derivate of cholesterol, 24S-hydroxycholesterol,
was measured in Fortasyn fed AD and WT mice [81]. Our
data indicate a higher elimination rate of brain cholesterol in
Fortasyn fed mice.
Thismay also explain the improvedwhitematter integrity
and preserved functional connectivity in both WT and AD
mice fed with Fortasyn. In support of this hypothesis, it has
been demonstrated that animals fed with a diet containing
uridine monophosphate (UMP), n3-LCPUFAs, and choline
showed increased levels of brain phospholipids, dendritic
spines, and neurite outgrowth [14–16].
5. Conclusions
Overall, the study presented here further proved that
two simultaneous protective mechanisms on vascular and
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synapse health are both enhanced by the specific Fortasyn
diet and may strengthen each other synergistically, indepen-
dent of the apoE genotype. The beneficial effect of these
diets is suggested to be caused by increased production
of phospholipids to sustain synaptic genesis and repair
processes [14, 82]. In this and other recent experiments, we
showed that a strong effect of these diets also involves the
amelioration of cerebrovascular health. Although decreased
cerebral perfusion has been recognized as an early and
important contributor to ADpathology and cognitive decline
[83], we believe that this aspect is not sufficiently considered
in human nutritional intervention studies. In our mice, we
have detected most of the pathological effects of apoE4 just
at 18 months of age, and therefore, most of the beneficial
effects of the diet were just present at 18 months of age.
It is important to stress that our apoE4 mouse model only
represents susceptibility to cognitive impairment and just like
in human apoE4 carriers multiple risk factors are required in
combination with apoE4 to precipitate disease pathology. For
future research it would therefore be interesting to study the
effect of the Fortasyn diet in older (24 months of age) apoE4
mice, in apoE4 mice with induced apoE4 comorbidities like
hypertension, stroke, or in apoE4 mice on high-fat diet or
in female apoE4 mice, resembling more closely the human
susceptibility to AD. For example, in clinical studies on brain
atrophy and clinical decline among cognitively normal older
individuals and individuals with mild cognitive impairment
and Alzheimer’s disease it has been shown that the presence
of apoE4 significantly accelerated rates of decline, andwomen
in all cohorts had higher rates of decline than men [84].
Additionally, a preclinical study revealed that expression of
human apoE4 renders aged mice fed with a western-type
diet more susceptible to sensorimotor deficits upon stroke
indicating an altered functional outcome following stroke in
apoE4 carriers [85]. Furthermore, this study demonstrated
the value of a multimodal approach, including advanced MR
neuroimaging tools, for detecting changes in brain structure
and function with respect to dietary intervention.
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